Brokerages expect that Omnicell Technologies (NASDAQ:OMCL) will announce earnings per share (EPS) of $0.27 for the current quarter, according to Zacks. Two analysts have made estimates for Omnicell Technologies’ earnings, with estimates ranging from $0.25 to $0.28. Omnicell Technologies reported earnings of $0.06 per share in the same quarter last year, which indicates a positive year over year growth rate of 350%. The firm is scheduled to report its next quarterly earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Omnicell Technologies will report full year earnings of $2.00 per share for the current year, with EPS estimates ranging from $1.94 to $2.04. For the next fiscal year, analysts expect that the company will post earnings of $2.39 per share, with EPS estimates ranging from $2.21 to $2.54. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Omnicell Technologies.
Omnicell Technologies (NASDAQ:OMCL) last released its earnings results on Thursday, February 1st. The company reported $0.54 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.52 by $0.02. Omnicell Technologies had a return on equity of 1.54% and a net margin of 2.88%. The firm had revenue of $198.26 million for the quarter, compared to analyst estimates of $205.50 million. During the same quarter last year, the firm posted $0.37 EPS. The company’s revenue was up 13.6% on a year-over-year basis.
A number of brokerages have commented on OMCL. Zacks Investment Research upgraded Omnicell Technologies from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Craig Hallum downgraded Omnicell Technologies from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $63.00 price objective on shares of Omnicell Technologies in a research report on Tuesday, April 3rd. Piper Jaffray raised their price objective on Omnicell Technologies from $38.00 to $44.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Finally, BidaskClub downgraded Omnicell Technologies from a “hold” rating to a “sell” rating in a research report on Friday, December 22nd. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Omnicell Technologies presently has an average rating of “Buy” and a consensus price target of $56.14.
Shares of OMCL stock opened at $43.90 on Tuesday. The company has a quick ratio of 1.28, a current ratio of 1.73 and a debt-to-equity ratio of 0.38. Omnicell Technologies has a 12 month low of $38.00 and a 12 month high of $55.40. The company has a market capitalization of $1,723.34, a price-to-earnings ratio of 243.89, a PEG ratio of 3.66 and a beta of 0.74.
In related news, Chairman Randall A. Lipps sold 8,186 shares of the firm’s stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $44.21, for a total transaction of $361,903.06. Following the completion of the transaction, the chairman now owns 224,206 shares in the company, valued at approximately $9,912,147.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Peter J. Kuipers sold 724 shares of the firm’s stock in a transaction that occurred on Thursday, April 12th. The stock was sold at an average price of $46.00, for a total value of $33,304.00. Following the transaction, the insider now owns 56,970 shares of the company’s stock, valued at approximately $2,620,620. The disclosure for this sale can be found here. Insiders have sold a total of 20,769 shares of company stock valued at $927,970 in the last 90 days. 3.71% of the stock is owned by corporate insiders.
Several institutional investors have recently bought and sold shares of OMCL. Carillon Tower Advisers Inc. bought a new position in shares of Omnicell Technologies during the 4th quarter worth approximately $38,612,000. Eagle Asset Management Inc. lifted its position in shares of Omnicell Technologies by 36.8% during the 4th quarter. Eagle Asset Management Inc. now owns 1,365,794 shares of the company’s stock worth $66,047,000 after buying an additional 367,687 shares during the period. Kennedy Capital Management Inc. lifted its position in shares of Omnicell Technologies by 199.2% during the 4th quarter. Kennedy Capital Management Inc. now owns 465,483 shares of the company’s stock worth $22,576,000 after buying an additional 309,913 shares during the period. Braun Stacey Associates Inc. bought a new position in shares of Omnicell Technologies during the 4th quarter worth approximately $9,391,000. Finally, BlackRock Inc. lifted its position in shares of Omnicell Technologies by 4.0% during the 4th quarter. BlackRock Inc. now owns 4,839,191 shares of the company’s stock worth $234,701,000 after buying an additional 187,069 shares during the period.
TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Expect Omnicell Technologies (OMCL) Will Post Earnings of $0.27 Per Share” was first published by Macon Daily and is owned by of Macon Daily. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://macondaily.com/2018/04/20/zacks-brokerages-expect-omnicell-technologies-omcl-will-post-earnings-of-0-27-per-share.html.
Omnicell Technologies Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Get a free copy of the Zacks research report on Omnicell Technologies (OMCL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Technologies and related companies with MarketBeat.com's FREE daily email newsletter.